• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在使用罗沙司他进行透析的情况下，低胆固醇水平是中枢性甲状腺功能减退的良好标志物。

Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat.

作者信息

Kita Serina, Okuyama Hiroshi, Kondo Takaya, Hayashi Mizuki, Nakao Shinichiro, Sawamura Toshitaka, Fujimoto Keiji, Nakagawa Atsushi, Yokoyama Hitoshi, Furuichi Kengo

机构信息

Department of Nephrology Kanazawa Medical University Kahoku-gun Japan.

Asanogawa General Hospital Kanazawa Japan.

出版信息

Clin Case Rep. 2024 Sep 3;12(9):e9400. doi: 10.1002/ccr3.9400. eCollection 2024 Sep.

DOI:10.1002/ccr3.9400
PMID:39229298
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11369681/
Abstract

Recently, hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors have been used for renal anemia, but side effects have also been reported. We report on the association of central hypothyroidism and cholesterol with roxadustat. Based on this case and previous reports, we believe that patients receiving roxadustat should have their thyroid function and cholesterol levels checked regularly.

摘要

最近，缺氧诱导因子脯氨酰羟化酶（HIF-PH）抑制剂已被用于治疗肾性贫血，但也有副作用的报道。我们报告了中枢性甲状腺功能减退和胆固醇与罗沙司他的关联。基于该病例及先前报道，我们认为接受罗沙司他治疗的患者应定期检查甲状腺功能和胆固醇水平。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/781b/11369681/bdd4dd45e2a6/CCR3-12-e9400-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/781b/11369681/bdd4dd45e2a6/CCR3-12-e9400-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/781b/11369681/bdd4dd45e2a6/CCR3-12-e9400-g001.jpg

相似文献

1
Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat.在使用罗沙司他进行透析的情况下，低胆固醇水平是中枢性甲状腺功能减退的良好标志物。
Clin Case Rep. 2024 Sep 3;12(9):e9400. doi: 10.1002/ccr3.9400. eCollection 2024 Sep.
2
Roxadustat-Induced Central Hypothyroidism in Renal Anemia Patients: Insights From Antineutrophil Cytoplasmic Antibody-Related Vasculitis Cases.罗沙司他诱导肾性贫血患者中枢性甲状腺功能减退：来自抗中性粒细胞胞浆抗体相关性血管炎病例的见解
Cureus. 2024 Jun 6;16(6):e61843. doi: 10.7759/cureus.61843. eCollection 2024 Jun.
3
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors and Hypothyroidism: An Analysis of the Japanese Pharmacovigilance Database.缺氧诱导因子脯氨酰羟化酶抑制剂与甲状腺功能减退症：日本药物警戒数据库分析。
In Vivo. 2024 Mar-Apr;38(2):917-922. doi: 10.21873/invivo.13519.
4
Disproportionality Analysis on Hypothyroidism With Roxadustat Using the Japanese Adverse Drug Event Database.罗沙司他致甲状腺功能减退症的比例失衡分析：利用日本不良药物事件数据库。
J Clin Pharmacol. 2023 Oct;63(10):1141-1146. doi: 10.1002/jcph.2300. Epub 2023 Jul 26.
5
Effect of Roxadustat on Thyroid Function in Patients With Renal Anemia.罗沙司他对肾性贫血患者甲状腺功能的影响。
J Clin Endocrinol Metab. 2023 Dec 21;109(1):e69-e75. doi: 10.1210/clinem/dgad483.
6
A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.缺氧诱导因子脯氨酰羟化酶抑制剂在透析慢性肾脏病中的疗效的网状荟萃分析。
Aging (Albany NY). 2023 Mar 27;15(6):2237-2274. doi: 10.18632/aging.204611.
7
Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis.罗沙司他治疗透析患者肾性贫血时抑制促甲状腺激素分泌。
BMC Nephrol. 2021 Mar 20;22(1):104. doi: 10.1186/s12882-021-02304-2.
8
Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.缺氧诱导因子脯氨酰羟化酶抑制剂罗沙司他的非临床特征：慢性肾脏病贫血的一种新治疗方法。
J Pharmacol Exp Ther. 2020 Aug;374(2):342-353. doi: 10.1124/jpet.120.265181. Epub 2020 Jun 2.
9
A Prospective Randomized Controlled Clinical Study to Investigate the Efficacy and Safety of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia Switched from Continuous Erythropoietin Receptor Activator Treatment.一项前瞻性随机对照临床研究，旨在调查缺氧诱导因子脯氨酰羟化酶抑制剂对从促红细胞生成素受体激动剂治疗转换而来的慢性心力衰竭合并肾性贫血非透析患者的疗效和安全性。
J Clin Med. 2024 May 8;13(10):2764. doi: 10.3390/jcm13102764.
10
Experience With the Use of a Novel Agent, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, for Posttransplant Anemia in Renal Transplant Recipients: A Case Report.新型药物——缺氧诱导因子脯氨酰羟化酶抑制剂治疗肾移植受者移植后贫血的经验：一例报告。
Transplant Proc. 2022 Mar;54(2):544-548. doi: 10.1016/j.transproceed.2021.10.022. Epub 2022 Feb 2.

引用本文的文献

1
Roxadustat Activates Thyroid Hormone Receptors α and β at Clinically Relevant Concentrations.罗沙司他在临床相关浓度下可激活甲状腺激素受体α和β。
Cureus. 2025 Aug 10;17(8):e89750. doi: 10.7759/cureus.89750. eCollection 2025 Aug.
2
Roxadustat-Induced Central Hypothyroidism Masked by Uremia at the Initiation of Hemodialysis: A Case Report.罗沙司他诱导的中枢性甲状腺功能减退在血液透析开始时被尿毒症掩盖：一例报告
Cureus. 2024 Dec 28;16(12):e76499. doi: 10.7759/cureus.76499. eCollection 2024 Dec.
3
Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study.

本文引用的文献

1
Effect of Roxadustat on Thyroid Function in Patients With Renal Anemia.罗沙司他对肾性贫血患者甲状腺功能的影响。
J Clin Endocrinol Metab. 2023 Dec 21;109(1):e69-e75. doi: 10.1210/clinem/dgad483.
2
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials.达普司他与常规促红细胞生成刺激剂治疗期间癌症安全性事件的分析：ASCEND-ND 和 ASCEND-D 试验的事后分析。
Nephrol Dial Transplant. 2023 Jul 31;38(8):1890-1897. doi: 10.1093/ndt/gfac342.
3
HIF-α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review.
罗沙司他在接受血液透析的患者中具有可逆性中枢性甲状腺功能减退的风险：一项单中心回顾性队列研究。
Ren Fail. 2024 Dec;46(2):2410375. doi: 10.1080/0886022X.2024.2410375. Epub 2024 Oct 8.
缺氧诱导因子-α脯氨酰羟化酶抑制剂及其在生物医学中的意义：综述
Biomedicines. 2021 Apr 24;9(5):468. doi: 10.3390/biomedicines9050468.
4
Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis.罗沙司他治疗透析患者肾性贫血时抑制促甲状腺激素分泌。
BMC Nephrol. 2021 Mar 20;22(1):104. doi: 10.1186/s12882-021-02304-2.
5
Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB).日本慢性肾脏病患者贫血的患病率：一项使用日本慢性肾脏病数据库（J-CKD-DB）数据的全国性横断面队列研究。
PLoS One. 2020 Jul 20;15(7):e0236132. doi: 10.1371/journal.pone.0236132. eCollection 2020.
6
Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?缺氧诱导因子脯氨酰羟化酶抑制剂：慢性肾脏病贫血治疗的范式转变？
Expert Opin Investig Drugs. 2020 Aug;29(8):831-844. doi: 10.1080/13543784.2020.1777276. Epub 2020 Jun 16.
7
Revealing a Mutant-Induced Receptor Allosteric Mechanism for the Thyroid Hormone Resistance.揭示甲状腺激素抵抗的突变诱导受体变构机制。
iScience. 2019 Oct 25;20:489-496. doi: 10.1016/j.isci.2019.10.002. Epub 2019 Oct 2.
8
Roles of HIFs and VEGF in angiogenesis in the retina and brain.低氧诱导因子（HIFs）和血管内皮生长因子（VEGF）在视网膜和脑中的血管生成中的作用。
J Clin Invest. 2019 Aug 12;129(9):3807-3820. doi: 10.1172/JCI126655.
9
Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity.缺氧诱导因子稳定化在预防早产儿视网膜病变中的比较系统药理学
Proc Natl Acad Sci U S A. 2016 May 3;113(18):E2516-25. doi: 10.1073/pnas.1523005113. Epub 2016 Apr 18.
10
Thyroid hormone regulation of metabolism.甲状腺激素对代谢的调节。
Physiol Rev. 2014 Apr;94(2):355-82. doi: 10.1152/physrev.00030.2013.